E. Ohman J or Asset Management AB Boosts Stock Position in Lantheus Holdings, Inc. $LNTH

E. Ohman J or Asset Management AB grew its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 56.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 29,238 shares of the medical equipment provider’s stock after purchasing an additional 10,506 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Lantheus were worth $1,500,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in LNTH. HighTower Advisors LLC grew its position in Lantheus by 107.8% during the first quarter. HighTower Advisors LLC now owns 4,797 shares of the medical equipment provider’s stock valued at $468,000 after buying an additional 2,488 shares during the period. Hsbc Holdings PLC purchased a new position in Lantheus in the first quarter valued at about $235,000. AlphaQuest LLC grew its position in shares of Lantheus by 252.5% during the 1st quarter. AlphaQuest LLC now owns 1,653 shares of the medical equipment provider’s stock valued at $161,000 after acquiring an additional 1,184 shares during the period. OMERS ADMINISTRATION Corp increased its stake in shares of Lantheus by 3.9% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 16,316 shares of the medical equipment provider’s stock worth $1,592,000 after purchasing an additional 616 shares during the last quarter. Finally, Vident Advisory LLC increased its stake in shares of Lantheus by 1,610.9% during the 1st quarter. Vident Advisory LLC now owns 47,427 shares of the medical equipment provider’s stock worth $4,629,000 after purchasing an additional 44,655 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have weighed in on LNTH. The Goldman Sachs Group set a $77.00 price objective on Lantheus and gave the company a “neutral” rating in a report on Wednesday, October 8th. B. Riley dropped their price target on Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research report on Tuesday, September 16th. Truist Financial increased their price target on Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Weiss Ratings cut Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. Finally, Mizuho upped their price objective on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and a consensus target price of $78.00.

Lantheus Stock Up 0.0%

Shares of NASDAQ LNTH opened at $66.71 on Friday. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. The company has a market cap of $4.42 billion, a P/E ratio of 28.03 and a beta of -0.10. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.29. The business has a 50-day simple moving average of $58.96 and a two-hundred day simple moving average of $62.23.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The firm had revenue of $92.51 million for the quarter. Research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.